Table 1 Patient characteristics among those with oropharyngeal squamous cell carcinoma based on sex and HPV status
Oropharynx HPV-associated | Oropharynx HPV - | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Male | Female | Male | Female | |||||||
Count | % | Count | % | p-value | Count | % | Count | % | p-value | |
Mean age (years) | 58,69 | 59,65 | < 0.001 | 60,74 | 61,66 | < 0.001 | ||||
Ethnicity | 0.006 | 0.32 | ||||||||
White | 10,997 | 94.0% | 1717 | 91.9% | 5167 | 86.0% | 1566 | 84.2% | ||
Black | 538 | 4.6% | 107 | 5.7% | 709 | 11.8% | 243 | 13.1% | ||
American Indian/Eskimo | 22 | 0.2% | 5 | 0.3% | 13 | 0.2% | 7 | 0.4% | ||
Asian/Pacific Islander | 103 | 0.9% | 28 | 1.5% | 87 | 1.4% | 32 | 1.7% | ||
Other | 45 | 0.4% | 12 | 0.6% | 32 | 0.5% | 11 | 0.6% | ||
Charlson/Deyo Score | < 0.001 | 0.72 | ||||||||
0 | 9957 | 84.3% | 1530 | 81.1% | 4817 | 79.5% | 1477 | 78.7% | ||
1 | 1486 | 12.6% | 272 | 14.4% | 942 | 15.6% | 304 | 16.2% | ||
2 | 365 | 3.1% | 84 | 4.5% | 297 | 4.9% | 96 | 5.1% | ||
AJCC Clinical Staging | ||||||||||
T Staging | < 0.001 | 0.002 | ||||||||
T0 | 85 | 0.7% | 13 | 0.7% | 16 | 0.3% | 6 | 0.3% | ||
T1 | 3225 | 27.4% | 582 | 31.1% | 1221 | 20.3% | 428 | 23.0% | ||
T2 | 4834 | 41.1% | 770 | 41.2% | 2097 | 34.9% | 671 | 36.0% | ||
T3 | 1925 | 16.4% | 254 | 13.6% | 1319 | 22.0% | 339 | 18.2% | ||
T4 | 1354 | 11.5% | 190 | 10.2% | 1180 | 19.7% | 380 | 20.4% | ||
TX | 326 | 2.8% | 61 | 3.3% | 170 | 2.8% | 38 | 2.0% | ||
N Staging | < 0.001 | < 0.001 | ||||||||
N0 | 1336 | 11.3% | 318 | 16.9% | 1410 | 23.4% | 594 | 31.7% | ||
N1 | 1874 | 15.9% | 424 | 22.5% | 997 | 16.5% | 344 | 18.3% | ||
N2 | 8023 | 68.1% | 1088 | 57.8% | 3298 | 54.6% | 877 | 46.8% | ||
N3 | 522 | 4.4% | 49 | 2.6% | 293 | 4.9% | 50 | 2.7% | ||
NX | 33 | 0.3% | 3 | 0.2% | 37 | 0.6% | 10 | 0.5% | ||
M Staging | 0.812 | 0.013 | ||||||||
M0 | 11,042 | 97.7% | 1763 | 98.0% | 5435 | 95.4% | 1718 | 96.7% | ||
M1 | 265 | 2.3% | 36 | 2.0% | 264 | 4.6% | 58 | 3.3% | ||
Primary Site | < 0.001 | 0.005 | ||||||||
Base of Tongue | 4845 | 41.0% | 611 | 32.4% | 2543 | 42.0% | 745 | 39.7% | ||
Tonsil | 6258 | 53.0% | 1150 | 61.0% | 2615 | 43.2% | 796 | 42.4% | ||
Other OP | 705 | 6.0% | 125 | 6.6% | 898 | 14.8% | 336 | 17.9% | ||
Insurance Status | < 0.001 | < 0.001 | ||||||||
Not Insured | 437 | 3.7% | 71 | 3.8% | 383 | 6.4% | 111 | 6.0% | ||
Private Insurance/Managed Care | 7264 | 62.2% | 989 | 52.9% | 2601 | 43.8% | 732 | 39.5% | ||
Medicaid | 753 | 6.4% | 162 | 8.7% | 703 | 11.8% | 240 | 13.0% | ||
Medicare | 2940 | 25.2% | 634 | 33.9% | 2121 | 35.7% | 750 | 40.5% | ||
Other Government | 290 | 2.5% | 12 | 0.6% | 132 | 2.2% | 18 | 1.0% | ||
Median Income Quartiles 2008–2012 | 0.002 | 0.043 | ||||||||
< $38,000 | 1472 | 12.5% | 274 | 14.6% | 1184 | 19.7% | 389 | 20.9% | ||
$38,000–$47,999 | 2443 | 20.8% | 435 | 23.1% | 1335 | 22.2% | 451 | 24.2% | ||
$48,000–$62,999 | 3265 | 27.7% | 488 | 25.9% | 1606 | 26.7% | 491 | 26.4% | ||
$63,000 + | 4588 | 39.0% | 685 | 36.4% | 1900 | 31.5% | 530 | 28.5% | ||
Urban/Rural 2013 | 0.190 | 0.27 | ||||||||
Metro | 9826 | 85.3% | 1573 | 84.8% | 5053 | 85.5% | 1539 | 84.0% | ||
Urban | 1488 | 12.9% | 259 | 14.0% | 775 | 13.1% | 265 | 14.5% | ||
Rural | 200 | 1.7% | 24 | 1.3% | 80 | 1.4% | 28 | 1.5% | ||
Facility Type | 0.214 | 0.346 | ||||||||
Community Cancer Program | 743 | 6.4% | 128 | 7.0% | 531 | 8.9% | 159 | 8.6% | ||
Comprehensive Community Cancer Program | 3719 | 31.8% | 596 | 32.7% | 2153 | 36.0% | 632 | 34.3% | ||
Academic/Research Program | 5810 | 49.7% | 907 | 49.8% | 2618 | 43.8% | 851 | 46.2% | ||
Integrated Network Cancer Program | 1407 | 12.0% | 192 | 10.5% | 671 | 11.2% | 199 | 10.8% | ||
Other specified types of cancer programs | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | ||
Facility Location | 0.110 | 0.130 | ||||||||
East | 2440 | 20.9% | 419 | 23.0% | 1223 | 20.5% | 398 | 21.6% | ||
South | 3915 | 33.5% | 610 | 33.5% | 2454 | 41.1% | 704 | 38.2% | ||
Midwest | 3196 | 27.4% | 493 | 27.0% | 1408 | 23.6% | 467 | 25.4% | ||
West | 2128 | 18.2% | 301 | 16.5% | 888 | 14.9% | 272 | 14.8% | ||
Treatment Group | < 0.001 | < 0.001 | ||||||||
No treatment | 210 | 1.8% | 31 | 1.6% | 286 | 4.7% | 90 | 4.8% | ||
Radiation only | 868 | 7.4% | 158 | 8.4% | 508 | 8.4% | 186 | 9.9% | ||
Radiation and Chemo | 7185 | 60.8% | 1011 | 53.6% | 3571 | 59.0% | 1004 | 53.5% | ||
Surgery and Radiation | 726 | 6.1% | 155 | 8.2% | 240 | 4.0% | 94 | 5.0% | ||
Surgery, Chemotherapy and Radiation | 2027 | 17.2% | 341 | 18.1% | 725 | 12.0% | 210 | 11.2% | ||
Surgery only | 572 | 4.8% | 155 | 8.2% | 464 | 7.7% | 218 | 11.6% | ||
Chemotherapy Only | 220 | 1.9% | 35 | 1.9% | 262 | 4.3% | 75 | 4.0% | ||